STAT+: A Decade Ago, These Drugs Tore Apart the FDA. Today, They Might Be some Patients’ Best Hope

Why It Matters

The positive trial results could expand therapeutic options for a disease with no cure, while reshaping regulatory and commercial approaches to rare‑genetic medicines.

Key Takeaways

• Exon‑skipping trials show functional improvement in 39 DMD patients.
• FDA approval process for exon‑skipping drugs sparked internal agency conflict.
• Sarepta Therapeutics generated $5.5 B from approved DMD therapies.
• CureDuchenne raised $1.3 M to fund early exon‑skipping research.
• New data may shift expert consensus on exon‑skipping efficacy.

Pulse Analysis

Exon skipping represents a clever genetic strategy that skips faulty sections of the dystrophin gene, allowing a shortened but functional protein to be produced in patients with Duchenne muscular dystrophy (DMD). The approach first ignited a fierce debate within the FDA when early candidates were fast‑tracked amid intense advocacy pressure, leading to internal disagreements over safety and efficacy standards. Over the past decade, companies such as Sarepta Therapeutics have navigated this regulatory turbulence, securing approvals that have generated billions in sales despite lingering questions about clinical benefit.

The latest open‑label trial, enrolling 39 boys with DMD—including the high‑profile case of Hawken Miller—delivered measurable gains in motor function and slowed disease progression, outcomes that many experts previously deemed unlikely. These findings have galvanized patient groups, notably CureDuchenne, whose grassroots fundraising of $1.3 million helped launch early research and sustain momentum. The data also validate the commercial model that has already produced $5.5 billion in revenue for Sarepta, suggesting a growing market appetite for rare‑disease therapies that can demonstrate tangible functional improvements.

Looking ahead, the trial’s success could prompt the FDA to refine its evidentiary thresholds for exon‑skipping drugs, potentially accelerating future approvals while maintaining rigorous post‑market surveillance. For investors and biotech firms, the results underscore the value of targeted genetic platforms and the importance of aligning with patient advocacy networks. Clinicians may soon have a more reliable therapeutic option for DMD, offering hope that the disease’s relentless trajectory can be altered, if not halted, through precision medicine.